Fresh Tracks Therapeutics (OTCPK:FRTX) - Aktienkurs, Nachrichten und Analyse

FRTX Aktienübersicht

Fresh Tracks Therapeutics, Inc. hat keine nennenswerte Geschäftstätigkeit.

FRTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 5.8% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung ($5M)

Fresh Tracks Therapeutics, Inc. Wettbewerber

Xenetic Biosciences

NasdaqCM:XBIO

US$5.9m

Scorpius Holdings

NYSEAM:SCPX

US$7.5m

Eiger BioPharmaceuticals

OTCPK:EIGR.Q

US$4.9m

Aditxt

NasdaqCM:ADTX

US$3.2m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Fresh Tracks Therapeutics
Historical stock prices
Current Share Price	US$0.93
52 Week High	US$1.10
52 Week Low	US$0.56
Beta	0.46
1 Month Change	-0.37%
3 Month Change	3.22%
1 Year Change	16.26%
3 Year Change	-97.51%
5 Year Change	n/a
Change since IPO	-99.56%

Aktuelle Nachrichten und Updates

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Aktionärsrenditen

	FRTX	US Biotechs	US Markt
7D	-1.1%	0.1%	1.2%
1Y	16.3%	7.1%	20.8%

Rendite im Vergleich zur Industrie: FRTX übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: FRTX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.5 erzielte.

Preisvolatilität

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement	5.0%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: FRTX hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: FRTXDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 12% auf 5% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2009	4	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. hat keine nennenswerte Geschäftstätigkeit. Zuvor beschäftigte sich das Unternehmen mit der Entwicklung verschiedener verschreibungspflichtiger Therapeutika für die Behandlung von Autoimmun- und Entzündungskrankheiten sowie anderen schwächenden Krankheiten in den Vereinigten Staaten. Fresh Tracks Therapeutics, Inc. wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in Boulder, Colorado.

Fresh Tracks Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Fresh Tracks Therapeutics im Vergleich zum Marktanteil des Unternehmens?
FRTX grundlegende Statistiken
Marktanteil	US$5.56m
Gewinn(TTM)	-US$5.69m
Umsatz(TTM)	US$8.01m

0.7x

Kurs-Umsatz-Verhältnis

-1.0x

Kurs-Gewinn-Verhältnis

Ist FRTX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
FRTX Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$8.01m
Kosten der Einnahmen	US$3.18m
Bruttogewinn	US$4.82m
Sonstige Ausgaben	US$10.52m
Umsatz	-US$5.69m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.95
Bruttomarge	60.25%
Nettogewinnspanne	-71.12%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich FRTX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

FRTX Aktienübersicht

Belohnungen

Risikoanalyse

Fresh Tracks Therapeutics, Inc. Wettbewerber

NasdaqCM:XBIO

US$5.9m

NYSEAM:SCPX

US$7.5m

OTCPK:EIGR.Q

US$4.9m

NasdaqCM:ADTX

US$3.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Erträge & Einnahmen